Vaginal mucosal immune system

The vaginal mucosal immune system is a specialized defense network in the female reproductive tract that protects against pathogens while maintaining tolerance to commensal microbes and sperm (NIH, 2020). It comprises a physical barrier of stratified squamous epithelium, innate sensors like Toll-like receptors (TLRs 1, 2, 4, 5, and 6), and a diverse array of immune cells, including tissue-resident memory T cells, dendritic cells, and macrophages (Journal of Immunology, 2010; NIH, 2020). Secreted factors such as immunoglobulin G (IgG), secretory leukocyte protease inhibitor (SLPI), and antimicrobial peptides like defensins and lactoferrin are critical for neutralizing viruses and bacteria (PubMed, 2012; ResearchGate, 2022). This system is highly dynamic and precisely regulated by sex hormones, such as estradiol and progesterone, throughout the menstrual cycle (NIH, 2020). Dysregulation, often involving the loss of protective Lactobacillus species or increased inflammation, is linked to a higher risk of acquiring sexually transmitted infections (STIs) such as HIV, HSV, and HPV (ResearchGate, 2026; Journal Watch, 2012). Therapeutic strategies targeting this system include mucosal vaccines, microbicides like tenofovir, and probiotics aimed at restoring homeostasis and enhancing local immunity (NIH, 2006; Frontiers in Immunology, 2021).

Other names

Female reproductive tract mucosal immunityVaginal immunityCervicovaginal immune systemVaginal mucosal immunityFemale genital tract mucosal immune system

Drugs targeting the vaginal mucosal immune system typically work by enhancing local innate defenses (e.g., TLR agonists), providing passive or active immunity (e.g., antibodies or vaccines), or restoring the protective commensal microbiota (e.g., probiotics) to prevent pathogen entry and replication.